^
Association details:
Biomarker:BCR-ABL1 E255K
Cancer:B Acute Lymphoblastic Leukemia
Drug:S81694 (TTK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

Published date:
11/06/2019
Excerpt:
S81694 induced significant apoptosis (70%) in the imatinib resistant BV173 cell line bearing the E255K-BCR-ABL1 mutation.
DOI:
https://doi.org/10.1182/blood-2019-125641